Despite requiring more API, the price of inhaled insulin Afrezza has dropped below that of injected rapid-acting rivals says MannKind's CEO, reporting a resilient Q3.
MannKind has spoken about Receptor Life Science, a newly-formed company which last month licensed the Technosphere inhaled delivery platform from the struggling firm.
Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.
Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.
MannKind says it is confident sales of its inhaled insulin product Afrezza - commercialised by Sanofi - will pick up after disappointing growth since launch.
MannKind has cut more jobs in efforts to streamline operations, leaving the inhalable insulin manufacturer around a third smaller than this time last year.
Pfizer’s Exubera may have muddied the waters but MannKind is confident a marketing push can help its inhaled insulin product Afrezza succeed after disappointing early sales.
Sanofi's inhaled insulin drug Affrezza has generated lower than expected revenue due to marketing delays rather than low demand according to MannKind CFO, Matthew Pfeffer.
MannKind’s development of new drugs with the delivery technology used in its inhalable insulin drug Afrezza will progress without founder Alfred Mann at the helm.
Two billion cartridges of inhaled insulin drug Afrezza will be manufactured annually by Mannkind, the firm says as it awaits final approval next month.
A US FDA review panel has recommended that Afrezza be approved and concluded that the technology used to deliver MannKind's inhalable insulin does not damage airways or lung cells.
US FDA has missed its review deadline for MannKind’s inhaled insulin candidate Afrezza after failing to complete inspection of third-party contract supplier.
MannKind’s share price tumbled by 31 per cent yesterday, just days after it published encouraging safety data for Afresa, because it revealed a partnership deal is unlikely to occur in 2009.
MannKind is trying to buy a Pfizer insulin facility for $33m (€26m) as it continues to push Afresa towards commercialisation but, like many things in the saga, the deal might not be straightforward.
MannKind, one of the inhaled-insulin market’s only remaining players, has posted higher than expected Q4 losses as costs for development of its lead product candidate Afresa increase ahead of its submission to the US FDA.
MannKind’s inhaled insulin treatment, Technosphere, has met its study goal in the first of three Phase III trials, leading to Pfizer transferring its remaining Exubera patients to the treatment.
Pfizer has updated the US product labeling of its inhaled insulin
treatment Exubera to include a warning of increased risk of lung
cancer among those using it.
Pfizer yesterday announced a multi-million dollar pay-off to
ex-partner Nektar Therapeutics, but the details of the deal reveal
not only Nektar's concerns for its future, but also that Pfizer is
still keeping its fingers in the...
UK-based Bespak, one of the two contract manufacturers of Pfizer's
inhaled insulin Exubera, confirmed on Friday it has been approached
by a potential buyer.
